Sandhya Srinivas, MD
Medical Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
- Since medical school
- 41 years
- Graduated 1985
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Srinivas’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A49392 · Current
Licensed to practise in California · since 1991 · expires 2027-03-31 · University of Madras, Madras Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Medical Oncology
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$120,156
Medicare paid this office $120,156 for 372 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 269 | $70,823 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $12,875 | $106 |
| Return visit (30+ min) | 69 | $9,585 | $79 |
| New patient visit (45+ min) | 58 | $8,455 | $146 |
| Long return visit (40+ min) | 34 | $6,846 | $171 |
See all 10 services
| Return visit (30+ min) | 269 | $70,823 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $12,875 | $106 |
| Return visit (30+ min) | 69 | $9,585 | $79 |
| New patient visit (45+ min) | 58 | $8,455 | $146 |
| Long return visit (40+ min) | 34 | $6,846 | $171 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $3,871 | $155 |
| New patient visit (60+ min) | 11 | $2,295 | $209 |
| New patient visit (45+ min) | 23 | $2,276 | $99 |
| Long return visit (40+ min) | 11 | $1,559 | $130 |
| Hospital discharge day management, 30 minutes or less | 13 | $962 | $74 |
Who their Medicare patients are
372 Original Medicare patients in 2024. Average age 76 · Under 65 5% · 85 and older 14% · Women 22% · Also on Medicaid 17% · Health risk score 2.20. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: Cancer 75% · High blood pressure 72% · Chronic kidney disease 38% · Coronary heart disease 33% · Diabetes 28% · Heart failure 19% · Atrial fibrillation 18% · Depression 15% · COPD 9% · Stroke 9% · Dementia 5%.
The office billed $652,893, Medicare allowed $158,711 and paid $120,156; for 1,041 services of 11 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 372 | 1,041 | 76 | 2.20 | $652,893 | $120,156 |
| 2023 | 359 | 1,066 | 75 | 2.21 | $609,552 | $98,262 |
| 2022 | 368 | 1,217 | 75 | 2.04 | $667,706 | $112,058 |
| 2021 | 380 | 1,223 | 76 | 2.54 | $636,897 | $106,116 |
| 2020 | 313 | 994 | 75 | 2.33 | $352,060 | $74,318 |
| 2019 | 314 | 869 | 75 | 2.19 | $138,928 | $68,705 |
| 2018 | 312 | 800 | 74 | 2.32 | $144,291 | $64,867 |
| 2017 | 302 | 740 | 75 | 2.33 | $157,120 | $57,352 |
| 2016 | 338 | 845 | 74 | 2.31 | $202,137 | $64,952 |
| 2015 | 365 | 930 | 73 | 2.16 | $230,760 | $71,826 |
| 2014 | 315 | 999 | 74 | 2.06 | $216,575 | $70,481 |
| 2013 | 356 | 1,188 | 74 | 2.10 | $267,968 | $82,972 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Return visit (30+ min) | 259 | $60,337 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 44 | $20,075 | $110 |
| New patient visit (45+ min) | 80 | $9,213 | $115 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,158 | $160 |
| Hospital discharge day management, 30 minutes or less | 31 | $2,505 | $76 |
2022: 8 services
| Return visit (30+ min) | 186 | $35,364 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 61 | $27,388 | $93 |
| Long return visit (40+ min) | 88 | $15,242 | $130 |
| Short return visit (20+ min) | 141 | $10,767 | $52 |
| New patient visit (45+ min) | 76 | $9,134 | $120 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 41 | $7,655 | $182 |
| Hospital discharge day management, 30 minutes or less | 33 | $2,265 | $67 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,080 | $98 |
2021: 9 services
| Return visit (30+ min) | 182 | $32,891 | $85 |
| Short return visit (20+ min) | 196 | $23,549 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 59 | $17,448 | $95 |
| Long return visit (40+ min) | 59 | $10,294 | $137 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $8,360 | $182 |
| New patient visit (45+ min) | 51 | $6,383 | $125 |
| Hospital discharge day management, more than 30 minutes | 15 | $1,501 | $100 |
| Hospital discharge day management, 30 minutes or less | 18 | $1,257 | $70 |
| New patient visit (30+ min) | 16 | $1,211 | $76 |
2020: 5 services
| Return visit (30+ min) | 238 | $50,896 | $68 |
| New patient visit (45+ min) | 77 | $8,932 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $5,282 | $98 |
| Return visit (30+ min) | 45 | $3,643 | $74 |
| Telehealth originating site facility fee | 14 | $298 | $21 |
2019: 5 services
| Return visit (30+ min) | 216 | $41,341 | $67 |
| New patient visit (45+ min) | 97 | $11,033 | $114 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $8,207 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,956 | $184 |
| Hospital discharge day management, 30 minutes or less | 17 | $1,148 | $68 |
2018: 5 services
| Return visit (30+ min) | 198 | $32,711 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $13,575 | $94 |
| New patient visit (45+ min) | 73 | $8,047 | $110 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $5,094 | $182 |
| Long return visit (40+ min) | 15 | $1,496 | $94 |
2017: 3 services
| Return visit (30+ min) | 193 | $34,174 | $67 |
| New patient visit (45+ min) | 89 | $10,026 | $113 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $7,572 | $93 |
2016: 5 services
| Return visit (30+ min) | 225 | $38,803 | $66 |
| New patient visit (45+ min) | 95 | $10,682 | $112 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $8,055 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,605 | $180 |
| Long return visit (40+ min) | 11 | $991 | $90 |
2015: 4 services
| Return visit (30+ min) | 229 | $39,349 | $64 |
| New patient visit (45+ min) | 119 | $12,914 | $109 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 38 | $11,437 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $5,059 | $181 |
2014: 2 services
| Return visit (30+ min) | 254 | $54,089 | $65 |
| New patient visit (45+ min) | 95 | $10,752 | $113 |
2013: 4 services
| Return visit (30+ min) | 279 | $62,734 | $63 |
| New patient visit (45+ min) | 100 | $10,724 | $107 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $5,991 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,268 | $174 |
Medicaid work
$8,500 in 2024
Medicaid paid $8,500 for 140 billed services this clinician did in 2024, up to 22 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 107 | $5,799 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 33 | $2,701 |
| 2024 | 140 | 2 | 22 | $8,500 |
| 2023 | 386 | 3 | 28 | $15,222 |
| 2022 | 240 | 1 | 25 | $9,591 |
| 2021 | 143 | 3 | 17 | $4,023 |
| 2020 | 90 | 1 | 20 | $2,569 |
| 2019 | 137 | 2 | 19 | $5,637 |
| 2018 | 39 | 1 | 12 | $1,815 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 306 | $12,207 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 50 | $1,532 |
| Long return visit (40+ min) | 30 | $1,483 |
2022
| Return visit (30+ min) | 240 | $9,591 |
2021
| Return visit (30+ min) | 68 | $2,305 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 35 | $1,089 |
| Short return visit (20+ min) | 40 | $629 |
2020
| Return visit (30+ min) | 90 | $2,569 |
2019
| Return visit (30+ min) | 92 | $3,158 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 45 | $2,479 |
2018
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 39 | $1,815 |
Drugs they prescribed that Part D paid
$723,334
Pharmacies billed $723,334 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
173 generic and fewer than 11 brand-name prescriptions · $723,334 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Cabometyx | 15 | $352,088 | $23,473 |
| Abiraterone Acetate | 19 | $13,622 | $717 |
| Bicalutamide | 18 | $657 | $36 |
| Dexamethasone | 20 | $215 | $11 |
| Prednisone | 31 | $211 | $7 |
See all 6 drugs
| Cabometyx | 15 | $352,088 | $23,473 |
| Abiraterone Acetate | 19 | $13,622 | $717 |
| Bicalutamide | 18 | $657 | $36 |
| Dexamethasone | 20 | $215 | $11 |
| Prednisone | 31 | $211 | $7 |
| Ondansetron | 15 | $55 | $4 |
Year by year
| 2024 | 221 | 63 | None | None | $723,334 |
| 2023 | 259 | 75 | 4% (11) | None | $680,501 |
| 2022 | 269 | 84 | 8% (21) | None | $583,039 |
| 2021 | 200 | 63 | 7% (13) | 17% | $442,347 |
| 2020 | 250 | 63 | 4% (11) | None | $976,161 |
| 2019 | 365 | 85 | 6% (22) | 42% | $1,471,180 |
| 2018 | 308 | 78 | 4% (12) | None | $1,386,582 |
| 2017 | 289 | 71 | None | 44% | $1,152,765 |
| 2016 | 332 | 80 | None | 37% | $962,942 |
| 2015 | 600 | 128 | None | None | $1,760,774 |
| 2014 | 733 | 119 | None | 42% | $2,181,395 |
| 2013 | 742 | 131 | 6% (41) | 33% | $1,278,516 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Abiraterone Acetate | 15 | $17,506 | $1,167 |
| Prednisone | 58 | $444 | $8 |
| Ondansetron | 16 | $148 | $9 |
| Dexamethasone | 11 | $131 | $12 |
2022: 6 drugs
| Cabometyx | 11 | $275,584 | $25,053 |
| Abiraterone Acetate | 23 | $116,647 | $5,072 |
| Prednisone | 48 | $481 | $10 |
| Levothyroxine | 20 | $229 | $11 |
| Ondansetron | 15 | $199 | $13 |
| Dexamethasone | 14 | $172 | $12 |
2021: 4 drugs
| Xtandi | 13 | $166,495 | $12,807 |
| Abiraterone Acetate | 26 | $96,666 | $3,718 |
| Bicalutamide | 14 | $650 | $46 |
| Prednisone | 46 | $446 | $10 |
2020: 4 drugs
| Xtandi | 31 | $346,369 | $11,173 |
| Zytiga | 17 | $193,617 | $11,389 |
| Abiraterone Acetate | 16 | $45,983 | $2,874 |
| Prednisone | 44 | $462 | $11 |
2019: 8 drugs
| Zytiga | 45 | $471,556 | $10,479 |
| Xtandi | 38 | $420,134 | $11,056 |
| Afinitor | 14 | $230,174 | $16,441 |
| Abiraterone Acetate | 16 | $56,202 | $3,513 |
| Eliquis | 15 | $7,578 | $505 |
| Prednisone | 55 | $545 | $10 |
| Dexamethasone | 13 | $235 | $18 |
| Ondansetron | 13 | $144 | $11 |
2018: 5 drugs
| Xtandi | 51 | $554,053 | $10,864 |
| Zytiga | 25 | $251,048 | $10,042 |
| Inlyta | 21 | $224,881 | $10,709 |
| Votrient | 11 | $135,530 | $12,321 |
| Prednisone | 25 | $228 | $9 |
2017: 7 drugs
| Xtandi | 57 | $536,435 | $9,411 |
| Votrient | 22 | $241,989 | $11,000 |
| Zytiga | 17 | $165,776 | $9,752 |
| Inlyta | 12 | $146,480 | $12,207 |
| Bicalutamide | 24 | $481 | $20 |
| Prednisone | 25 | $174 | $7 |
| Tamsulosin | 13 | $151 | $12 |
2016: 9 drugs
| Xtandi | 54 | $487,034 | $9,019 |
| Votrient | 14 | $105,515 | $7,537 |
| Zytiga | 12 | $105,341 | $8,778 |
| Tamsulosin | 17 | $640 | $38 |
| Bicalutamide | 25 | $526 | $21 |
| Dexamethasone | 16 | $228 | $14 |
| Prednisone | 21 | $188 | $9 |
| Ondansetron | 13 | $135 | $10 |
| Prochlorperazine Maleate | 20 | $113 | $6 |
2015: 15 drugs
| Xtandi | 83 | $726,368 | $8,751 |
| Zytiga | 53 | $423,470 | $7,990 |
| Inlyta | 27 | $250,433 | $9,275 |
| Votrient | 24 | $170,469 | $7,103 |
| Sutent | 13 | $95,830 | $7,372 |
| Bicalutamide | 40 | $1,090 | $27 |
| Hydrocortisone | 13 | $581 | $45 |
| Tamsulosin | 11 | $534 | $49 |
| Prednisone | 55 | $462 | $8 |
| Ondansetron | 15 | $309 | $21 |
| Megestrol Acetate | 12 | $187 | $16 |
| Dexamethasone | 15 | $138 | $9 |
| Alendronate | 15 | $111 | $7 |
| Prochlorperazine Maleate | 11 | $66 | $6 |
| Lorazepam | 12 | $28 | $2 |
2014: 16 drugs
| Zytiga | 84 | $633,775 | $7,545 |
| Inlyta | 49 | $487,256 | $9,944 |
| Xtandi | 52 | $425,575 | $8,184 |
| Votrient | 32 | $249,427 | $7,795 |
| Sutent | 23 | $130,192 | $5,661 |
| Bicalutamide | 71 | $2,667 | $38 |
| Hydrocortisone | 17 | $1,048 | $62 |
| Prednisone | 80 | $796 | $10 |
| Nystatin | 17 | $720 | $42 |
| Ondansetron | 26 | $493 | $19 |
| Potassium Chloride | 13 | $348 | $27 |
| Megestrol Acetate | 13 | $290 | $22 |
| Levothyroxine | 23 | $275 | $12 |
| Gabapentin | 12 | $206 | $17 |
| Lisinopril | 28 | $142 | $5 |
| Prochlorperazine Maleate | 17 | $122 | $7 |
2013: 21 drugs
| Zytiga | 71 | $403,774 | $5,687 |
| Votrient | 45 | $323,994 | $7,200 |
| Inlyta | 13 | $121,324 | $9,333 |
| Afinitor | 12 | $106,834 | $8,903 |
| Xtandi | 13 | $99,679 | $7,668 |
| Nilandron | 25 | $80,024 | $3,201 |
| Emend | 20 | $6,693 | $335 |
| Bicalutamide | 57 | $3,679 | $65 |
| Hydrocortisone | 27 | $1,163 | $43 |
| Dexamethasone | 14 | $1,002 | $72 |
| Megestrol Acetate | 15 | $884 | $59 |
| Ketoconazole | 12 | $831 | $69 |
| Tamsulosin | 11 | $684 | $62 |
| Nystatin | 12 | $524 | $44 |
| Ondansetron | 19 | $435 | $23 |
| Prednisone | 65 | $373 | $6 |
| Alendronate | 38 | $367 | $10 |
| Hydrocodone-Acetaminophen | 15 | $258 | $17 |
| Prochlorperazine Maleate | 25 | $176 | $7 |
| Lorazepam | 27 | $147 | $5 |
| Levothyroxine | 11 | $132 | $12 |
Money from drug and device companies
$14,497 in 2025
| 2025 | 11 | 23 | $12,670 | $14,497 |
| 2024 | 7 | 24 | $13,631 | $36,119 |
| 2023 | 10 | 19 | $19,361 | $20,843 |
| 2022 | 12 | 27 | $30,379 | $31,265 |
| 2021 | 10 | 20 | $36,654 | $36,785 |
| 2020 | 9 | 23 | $25,587 | $26,151 |
| 2019 | 9 | 67 | $44,097 | $53,854 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Erleada | $4,230 | 2 payments
|
| Merck Sharp & Dohme | None | $3,103 | 9 payments
|
| Janssen Research & Development | None | $2,300 | 1 payment
|
| Astellas Pharma Global Development | Xtandi | $2,100 | 1 payment
|
| Janssen Scientific Affairs | Erleada | $1,918 | 2 payments
|
| Aveo Pharmaceuticals | Fotivda | $268 | 2 payments
|
See all 23 published payments
| Astellas Pharma Global Development | Consulting · 2025-12-12 | Xtandi | $2,100 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-04 | Opdivo | $32 |
| Aveo Pharmaceuticals | Meals · 2025-11-20 | Fotivda | $151 |
| Astellas Pharma US | Meals · 2025-11-20 | Xtandi | $126 |
| Pfizer | Meals · 2025-10-29 | Xtandi | $27 |
| Janssen Research & Development | Consulting · 2025-10-02 | None | $2,300 |
| Merck Sharp & Dohme | Consulting · 2025-07-23 | None | $2,240 |
| Caris MPI | Meals · 2025-07-10 | Mi Cancer Seek | $69 |
| Janssen Scientific Affairs | Consulting · 2025-06-18 | Erleada | $1,800 |
| Janssen Biotech | Consulting · 2025-06-13 | Erleada | $1,763 |
| Janssen Scientific Affairs | Meals · 2025-06-03 | Erleada | $118 |
| Aveo Pharmaceuticals | Meals · 2025-06-01 | Fotivda | $117 |
| Exelixis | Meals · 2025-05-31 | Cabometyx | $175 |
| Merck Sharp & Dohme | Travel · 2025-04-23 | None | $43 |
| Merck Sharp & Dohme | Meals · 2025-04-09 | None | $65 |
| Merck Sharp & Dohme | Meals · 2025-04-09 | None | $15 |
| Merck Sharp & Dohme | Meals · 2025-04-09 | None | $35 |
| Merck Sharp & Dohme | Travel · 2025-04-08 | None | $259 |
| Merck Sharp & Dohme | Travel · 2025-04-08 | None | $156 |
| Merck Sharp & Dohme | Travel · 2025-04-08 | None | $205 |
| Merck Sharp & Dohme | Meals · 2025-04-08 | None | $85 |
| Janssen Biotech | Consulting · 2025-02-28 | None | $2,468 |
| Pfizer | Meals · 2025-02-14 | None | $149 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $36,119
| Ge Healthcare | None | $18,965 | 7 payments
|
| Telix Pharmaceuticals | Illuccix | $5,445 | 9 payments
|
| Eli Lilly and | None | $4,500 | 1 payment
|
| Novartis Pharmaceuticals | None | $3,039 | 4 payments
|
| Janssen Scientific Affairs | None | $2,227 | 1 payment
|
| Pfizer | None | $1,908 | 1 payment
|
| Aveo Pharmaceuticals | Fotivda | $34 | 1 payment
|
2023: $20,843
| Novartis Pharmaceuticals | Pluvicto | $5,392 | 2 payments
|
| Eli Lilly and | None | $3,600 | 1 payment
|
| Seagen | Padcev | $3,244 | 3 payments
|
| Pfizer | None | $3,124 | 4 payments
|
| Eisai | Lenvima | $2,401 | 2 payments
|
| Janssen Scientific Affairs | None | $2,296 | 2 payments
|
| AVEO Pharmaceuticals | Fotivda | $284 | 2 payments
|
| Galvanize Therapeutics | Aliya System | $221 | 1 payment
|
| Exelixis | Cabometyx | $162 | 1 payment
|
| Telix Pharmaceuticals | Illuccix | $119 | 1 payment
|
2022: $31,265
| Eli Lilly and | None | $7,200 | 1 payment
|
| Merck Sharp & Dohme | Lynparza | $6,450 | 7 payments
|
| Johnson & Johnson Health Care Systems | None | $3,500 | 3 payments
|
| BeiGene USA | None | $3,500 | 2 payments
|
| Seagen | Padcev | $3,184 | 4 payments
|
| AVEO Pharmaceuticals | Fotivda | $2,931 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $1,353 | 2 payments
|
| Jazz Pharmaceuticals | None | $1,240 | 1 payment
|
| Pfizer | None | $954 | 1 payment
|
| Janssen Scientific Affairs | Erleada | $825 | 1 payment
|
| Progenics Pharmaceuticals | Pylarify | $94 | 1 payment
|
| Astellas Pharma US | Padcev | $34 | 1 payment
|
2021: $36,785
| Pfizer | None | $8,673 | 5 payments
|
| Merck Sharp & Dohme | Keytruda | $6,707 | 4 payments
|
| Eisai | Lenvima | $5,313 | 3 payments
|
| Bayer HealthCare Pharmaceuticals | Xofigo | $5,264 | 1 payment
|
| Novartis Pharmaceuticals | None | $3,144 | 1 payment
|
| Hra Pharma Rare Diseases | Lysodren | $2,000 | 1 payment
|
| Seagen | Padcev | $1,975 | 2 payments
|
| Aveo Pharmaceuticals | Fotivda | $1,400 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $1,300 | 1 payment
|
| Janssen Scientific Affairs | Erleada | $1,010 | 1 payment
|
2020: $26,151
| Bayer HealthCare Pharmaceuticals | Nubeqa | $6,337 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $4,388 | 2 payments
|
| Eisai | Lenvima | $3,591 | 5 payments
|
| Pfizer | Bavencio | $3,578 | 2 payments
|
| Exelixis | Cabometyx | $2,227 | 4 payments
|
| Seagen | Padcev | $2,034 | 2 payments
|
| HRA Pharma Rare Diseases | Lysodren | $1,500 | 1 payment
|
| Merck Sharp & Dohme | None | $1,500 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $998 | 1 payment
|
2019: $53,854
| Eisai | Lenvima | $12,683 | 16 payments
|
| Pfizer | Bavencio | $9,396 | 6 payments
|
| Bayer HealthCare Pharmaceuticals | Non-Covered | $8,460 | 14 payments
|
| Merck Sharp & Dohme | None | $6,738 | 8 payments
|
| Janssen Biotech | Balversa | $6,677 | 10 payments
|
| Genentech | Tecentriq | $5,638 | 6 payments
|
| Janssen Scientific Affairs | Erleada | $2,495 | 3 payments
|
| Genentech USA | Non-Covered Product | $1,231 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $537 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Merck Sharp & Dohme LLC · A Multi-Center, Double-Blind, Randomized Phase 3 Study To Compare the Efficacy and Safety of Belzutifan Mk-6482 Plus Pembrolizumab Mk- 3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma Ccrcc Post Nephrectomy 6482-022 · 2023 | Their institution | $485,076 |
| Regeneron Pharmaceuticals, Inc. · Phase 1/2 Study of Regn4336 (A Psmaxcd3 Bispecific Antibody) Administered Alone Or in Combination With Cemiplimab in Patients With Metastatic Castration-Resistant Prostate Cancer · 2025 | Their institution | $461,431 |
| Celgene Corporation · Ph I Fih Mcrpc Mono Cc-94676-Pca-001 - A Phase 1, Multi-Center, Open-Label, Dose Finding Study To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cc-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer · 2023 | Their institution | $455,555 |
| Merck Sharp & Dohme LLC · A Multicenter, Double-Blind, Randomized Phase 3 Study To Compare the Efficacy and Safety of Belzutifan Mk-6482 Plus Pembrolizumab Mk-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma Ccrcc Post Nephrectomy Mk-6482-022 · 2024 | Their institution | $410,802 |
| Merck Sharp & Dohme Corporation · A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab Mk-3475 As Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy · 2019 | Their institution | $409,436 |
| Exelixis Inc. · Study of Cabozantinib in Combination With Atezolizumab To Subjects With Locally Advanced Or Metastatic Solid Tumors · 2020 | Their institution | $356,846 |
| Merck Sharp & Dohme LLC · A Phase 3, Randomized, Open-Label Study To Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab Mk-3475 Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-Eligible Participants With Muscle-Invasive Bladder Cancer Keynote-B15 , Ev-304 · 2023 | Their institution | $320,541 |
| Seagen Inc. · A Dose-Escalation and Dose-Expansion Study of Enfortumab Vedotin (Asg-22ce) in Combination With Pembrolizumab and/Or Chemotherapy for Treatment of Patients With Locally Advanced Or Metastatic Urothelial Cancer · 2020 | Their institution | $301,624 |
| Regeneron Pharmaceuticals, Inc. · Phase 1/2 Study of Regn4336 (A Psmaxcd3 Bispecific Antibody) Administered Alone Or in Combination With Cemiplimab in Patients With Metastatic Castration-Resistant Prostate Cancer · 2023 | Their institution | $298,122 |
| Seagen Inc. · A Dose-Escalation and Dose-Expansion Study of Enfortumab Vedotin (Asg-22ce) in Combination With Pembrolizumab and/Or Chemotherapy for Treatment of Patients With Locally Advanced Or Metastatic Urothelial Cancer · 2023 | Their institution | $282,043 |
| JAZZ PHARMACEUTICALS INC. · Emerge-201: A Phase 2, Multicenter, Open-Label Study of Lurbinectedin Efficacy and Safety in Participants With Advanced Or Metastatic Solid Tumors · 2023 | Their institution | $265,255 |
| Merck Sharp & Dohme LLC · A Phase 3, Randomized, Open-Label Study To Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab Mk-3475 Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-Eligible Participants With Muscle-Invasive Bladder Cancer Keynote-B15 , Ev-304 · 2024 | Their institution | $250,092 |
| AstraZeneca Pharmaceuticals LP · Neoadjuvant Durvalumab and Chemotherapy in Variant Histology Muscle Invasive Bladder Cancer · 2019 | Their institution | $237,932 |
| Seattle Genetics, Inc. · A Dose-Escalation and Dose-Expansion Study of Enfortumab Vedotin Asg-22ce in Combination With Pembrolizumab Andor Chemotherapy for Treatment of Patients With Locally Advanced Or Metastatic Urothelial Cancer · 2019 | Their institution | $230,446 |
| JAZZ PHARMACEUTICALS INC. · Emerge-201: A Phase 2, Multicenter, Open-Label Study of Lurbinectedin Efficacy and Safety in Participants With Advanced Or Metastatic Solid Tumors · 2024 | Their institution | $213,197 |
| Seagen Inc. · A Dose-Escalation and Dose-Expansion Study of Enfortumab Vedotin (Asg-22ce) in Combination With Pembrolizumab and/Or Chemotherapy for Treatment of Patients With Locally Advanced Or Metastatic Urothelial Cancer · 2021 | Their institution | $208,761 |
| Merck Sharp & Dohme LLC · A Phase 3, Randomized, Open-Label Study To Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab Mk-3475 Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-Eligible Participants With Muscle-Invasive Bladder Cancer Keynote-B15 , Ev-304 · 2022 | Their institution | $183,398 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Open-Label, Multi-Center, Global Study To Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed By Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer · 2020 | Their institution | $177,979 |
| Merck Sharp & Dohme LLC · A Multi-Center, Double-Blind, Randomized Phase 3 Study To Compare the Efficacy and Safety of Belzutifan Mk-6482 Plus Pembrolizumab Mk- 3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma Ccrcc Post Nephrectomy 6482-022 · 2022 | Their institution | $174,217 |
| Celgene Corporation · Ph I Fih Mcrpc Mono Cc-94676-Pca-001 - A Phase 1, Multi-Center, Open-Label, Dose Finding Study To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cc-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer · 2024 | Their institution | $166,717 |
| Regeneron Pharmaceuticals, Inc. · Phase 1/2 Study of Regn4336 (A Psmaxcd3 Bispecific Antibody) Administered Alone Or in Combination With Cemiplimab in Patients With Metastatic Castration-Resistant Prostate Cancer · 2024 | Their institution | $163,965 |
| Merck Sharp & Dohme LLC · A Phase 3, Randomized, Open-Label Study of Mk-5684 Versus Alternative Abiraterone Acetate Or Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer Mcrpc That Progressed on Or After Prior Treatment With One Next Generation Hor · 2025 | Their institution | $159,386 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Open-Label, Multi-Center, Global Study To Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed By Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer · 2021 | Their institution | $149,507 |
| PFIZER INC. · A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib in Combination With Physicians Choice of Enzalutamide Or Abiraterone Acetateprednisone in Metastatic Castrationresistant Prostate Cancer With Dna Damage Repair Deficiencies · 2020 | Their institution | $147,057 |
| Eisai Inc. · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus Or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma · 2019 | Their institution | $141,188 |
| Exelixis Inc. · A Phase 1b Dose Escalation Study of Cabozantinib (Xl184) Administered Alone Or in Combination With Atezolizumab To Subjects With Locally Advanced Or Metastatic Solid Tumors · 2024 | Their institution | $137,269 |
| Merck Sharp & Dohme LLC · A Phase 3, Randomized, Open-Label Study To Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab Mk-3475 Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-Eligible Participants With Muscle-Invasive Bladder Cancer Keynote-B15 , Ev-304 · 2025 | Their institution | $131,522 |
| Exelixis Inc. · A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (Xl184) in Combination With Atezolizumab Vs Second Novel Hormonal Therapy (Nht) in Subjects With Metastatic Castration-Resistant Prostate Cancer · 2023 | Their institution | $128,256 |
| Exelixis Inc. · Study of Cabozantinib in Combination With Atezolizumab To Subjects With Locally Advanced Or Metastatic Solid Tumors · 2019 | Their institution | $122,979 |
| Bayer HealthCare Pharmaceuticals Inc. · Bay 1841788, Mhspc · 2022 | Their institution | $114,932 |
| E.R. Squibb & Sons, L.L.C. · A Phase 1, Multi-Center, Open-Label, Dose Finding Study To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cc-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer · 2025 | Their institution | $112,756 |
| Exelixis Inc. · A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of Xl092 in Subjects With Inoperable Locally Advanced Or Metastatic Solid Tumors · 2024 | Their institution | $108,812 |
| Exelixis Inc. · A Randomized, Open-Label, Controlled Study of Cabozantinib (Xl184) in Combination With Atezolizumab Vs Second Novel Hormonal Therapy (Nht) in Subjects With High-Risk, Metastatic Castration-Resistant Prostate Cancer · 2025 | Their institution | $102,656 |
| Merck Sharp & Dohme Corporation · A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (Mk-3475) As Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy · 2019 | Their institution | $97,477 |
| Astellas Pharma Global Development · A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of Asg-22ce Given As Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 · 2020 | Their institution | $96,298 |
| E.R. Squibb & Sons, L.L.C. · Phase III Rcc Monotherapy Vs. Everolimus Ono 4538-03 · 2020 | Their institution | $91,231 |
| Celgene Corporation · A Phase 1, Multi-Center, Open-Label, Dose Finding Study To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cc-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer · 2025 | Their institution | $84,284 |
| Merck Sharp & Dohme Corporation · A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab Mk-3475 As Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy · 2020 | Their institution | $79,880 |
| Seagen Inc. · A Dose-Escalation and Dose-Expansion Study of Enfortumab Vedotin (Asg-22ce) in Combination With Pembrolizumab and/Or Chemotherapy for Treatment of Patients With Locally Advanced Or Metastatic Urothelial Cancer · 2022 | Their institution | $77,706 |
| Exelixis Inc. · A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (Xl184) in Combination With Atezolizumab Vs Second Novel Hormonal Therapy (Nht) in Subjects With Metastatic Castration-Resistant Prostate Cancer · 2022 | Their institution | $76,337 |
| Aveo Pharmaceuticals, Inc. · Tinivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib in Combination With Nivolumab To Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One Or Two Lines of Therapy Where One Line Has An Immune Checkpoint Inhibitor · 2023 | Their institution | $75,865 |
| AstraZeneca Pharmaceuticals LP · Neoadjuvant Durvalumab and Chemotherapy in Variant Histology Muscle Invasive Bladder Cancer · 2020 | Their institution | $74,400 |
| Genentech, Inc. · Phase III Ipatasertib Plus Abirateron in Mcrpc 1st Line · 2019 | Their institution | $72,642 |
| Clovis Oncology, Inc. · A Study of Rucaparib in Patients With Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Gene Deficiency (Triton2) · 2019 | Their institution | $71,291 |
| Regeneron Pharmaceuticals, Inc. · Phase 1/2 Study of Regn4336 (A Psmaxcd3 Bispecific Antibody) Administered Alone Or in Combination With Cemiplimab in Patients With Metastatic Castration-Resistant Prostate Cancer · 2022 | Their institution | $69,283 |
| E.R. Squibb & Sons, L.L.C. · Ph 1 Study in Metastatic Castration-Resistant Prostate Cancer · 2024 | Their institution | $67,489 |
| Genentech, Inc. · Phase III Ipatasertib Plus Abirateron in Mcrpc 1st Line · 2020 | Their institution | $65,583 |
| AstraZeneca Pharmaceuticals LP · Neoadjuvant Durvalumab and Chemotherapy in Variant Histology Muscle Invasive Bladder Cancer · 2022 | Their institution | $56,165 |
| Exelixis Inc. · Study of Cabozantinib in Combination With Atezolizumab To Subjects With Locally Advanced Or Metastatic Solid Tumors · 2022 | Their institution | $51,727 |
| Exelixis Inc. · A Randomized, Open-Label, Controlled Study of Cabozantinib (Xl184) in Combination With Atezolizumab Vs Second Novel Hormonal Therapy (Nht) in Subjects With High-Risk, Metastatic Castration-Resistant Prostate Cancer · 2024 | Their institution | $51,422 |
| E.R. Squibb & Sons, L.L.C. · A Phase 1, Open-Label Study of Bms-986460 in Participants With Metastatic Castration-Resistant Prostate Cancer · 2025 | Their institution | $50,591 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Open-Label, Multi-Center, Global Study To Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed By Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer · 2022 | Their institution | $48,420 |
| AstraZeneca Pharmaceuticals LP · Study of Medi4736 Durvalumab With Or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer · 2019 | Their institution | $40,228 |
| Clovis Oncology, Inc. · A Study of Rucaparib in Patients With Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Gene Deficiency (Triton2) · 2020 | Their institution | $39,714 |
| Astellas Pharma Global Development · A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of Asg-22ce Given As Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Maligt Solid Tumors That Express Nectin-4 · 2022 | Their institution | $39,142 |
| Merck Sharp & Dohme LLC · A Multicenter, Double-Blind, Randomized Phase 3 Study To Compare the Efficacy and Safety of Belzutifan Mk-6482 Plus Pembrolizumab Mk-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma Ccrcc Post Neph · 2025 | Their institution | $37,618 |
| AstraZeneca Pharmaceuticals LP · Study of Medi4736 Durvalumab With Or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer · 2020 | Their institution | $35,821 |
| E.R. Squibb & Sons, L.L.C. · Phase III Rcc 1l Combo · 2020 | Their institution | $32,207 |
| Clovis Oncology, Inc. · Rucaparib in Patients With Locally Advanced Or Metastatic Urothelial Carcinoma (Atlas) · 2019 | Their institution | $31,744 |
| Bayer Healthcare Pharmaceuticals Inc. · Bay 1841788, Mhspc · 2023 | Their institution | $30,038 |
| Merck Sharp & Dohme LLC · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab Mk-3475 As Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy Keynote-564 · 2024 | Their institution | $28,809 |
| Merck Sharp & Dohme Corporation · A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab Mk-3475 As Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy · 2021 | Their institution | $28,401 |
| PFIZER INC. · A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib With Enzalutamide in Metastatic Castrationresistant Prostate Cancer · 2022 | Their institution | $28,374 |
| E.R. Squibb & Sons, L.L.C. · Ph-2 Dose Range With Population Pk in Rcc · 2024 | Their institution | $28,108 |
| Bayer HealthCare Pharmaceuticals Inc. · Bay 1841788 Mhspc · 2019 | Their institution | $26,797 |
| Janssen Research & Development, LLC · A Phase 2, Two-Arm Multicenter, Open-Label Study To Determine the Efficacy and the Safety of Two Different Dose Regimens of A Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 in Subjects With Metastatic Or Surgically Unresectable Urothelial Cancer With Fgfr Genomic Alterations · 2019 | Their institution | $26,305 |
| Merck Sharp & Dohme LLC · Mk-5684-003# A Phase 3 Randomized, Open-Label Study of Mk-5684 Versus Alternative Abiraterone Acetate Or Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer Mcrpc Previously Treated With Next-Generation Hormonal Agent Nha · 2025 | Their institution | $25,574 |
| PFIZER INC. · A Phase 3 Randomized Openlabel Study of Pf06821497 Mevrometostat in Combination With Enzalutamide Compared With Enzalutamide Or Docetaxel in Participants With Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone Acetate Mevpro1 · 2025 | Their institution | $25,182 |
| Astellas Pharma Global Development · A Phase 2 Open-Label Extension Study for Subjects With Prostate Cancer Who Previously Participated in An Enzalutamide Clinical Study · 2020 | Their institution | $24,944 |
| Eisai Inc. · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus Or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (Clear) · 2023 | Their institution | $24,719 |
| Clovis Oncology, Inc. · A Study of Rucaparib in Patients With Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Gene Deficiency (Triton2) · 2021 | Their institution | $24,436 |
| E.R. Squibb & Sons, L.L.C. · Ph-2 Dose Range With Population Pk in Rcc · 2021 | Their institution | $24,347 |
| Bayer HealthCare Pharmaceuticals Inc. · Bay 1841788 Mhspc · 2020 | Their institution | $24,201 |
| Bayer HealthCare Pharmaceuticals Inc. · Darolutamide Roll Over Study · 2022 | Their institution | $22,870 |
| Novartis Pharmaceuticals Corporation · A Randomized Double Blind Placebo Controlled Phase III Study To Evaluate the Efficacy and Safety of Pazopanib As Adjuvant Therapy for Subjects With Localized Or Locally Advanced Rcc Following Nephrectomy · 2019 | Their institution | $22,698 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Open-Label, Multi-Center, Global Study To Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed By Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer · 2024 | Their institution | $21,246 |
| E.R. Squibb & Sons, L.L.C. · Phase III Rcc Monotherapy Vs. Everolimus Ono 4538-03 · 2019 | Their institution | $20,318 |
| Merck Sharp & Dohme LLC · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab Mk-3475 As Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy Keynote-564 · 2022 | Their institution | $19,214 |
| AstraZeneca Pharmaceuticals LP · Study of Medi4736 Durvalumab With Or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer · 2021 | Their institution | $16,094 |
| Merck Sharp & Dohme LLC · A Phase 3 Randomized, Open-Label Study of Mk-5684 Versus Alternative Abiraterone Acetate Or Enzalutamide in Participants With Metastatic Castration Resistant Prostate Cancer Mcrpc Previously Treated With Next-Generation Hormonal Agent Nha and Taxane-Based Chemotherapy. · 2024 | Their institution | $15,840 |
| Genentech, Inc. · Bladder Cancer · 2019 | Their institution | $15,277 |
| Aveo Pharmaceuticals, Inc. · Tinivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib in Combination With Nivolumab To Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One Or Two Lines of Therapy Where One Line Has An Immune Checkpoint Inhibitor · 2025 | Their institution | $14,763 |
| Genentech, Inc. · Atezolizumab in Muscle Invasive Bladder Cancer Mibc · 2019 | Their institution | $14,459 |
| Genentech, Inc. · Atezolizumab in Muscle Invasive Bladder Cancer Mibc · 2020 | Their institution | $14,207 |
| Exelixis Inc. · A Phase 1b Dose Escalation Study of Cabozantinib Xl184 Administered Alone Or in Combination With Atezolizumab To Subjects With Locally Advanced Or Metastatic Solid Tumors · 2019 | Their institution | $14,159 |
| Aveo Pharmaceuticals, Inc. · Tinivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib in Combination With Nivolumab To Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One Or Two Lines of Therapy Where One Line Has An Immune Checkpoint Inhibitor · 2024 | Their institution | $12,913 |
| E.R. Squibb & Sons, L.L.C. · Ph III Rcc 1l Combo - A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced Or Metastatic Renal Cell Carcinoma · 2022 | Their institution | $12,160 |
| E.R. Squibb & Sons, L.L.C. · Phase III Rcc 1l Combo · 2019 | Their institution | $12,160 |
| Eisai Inc. · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus Or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma · 2020 | Their institution | $12,111 |
| Merck Sharp & Dohme LLC · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab Mk-3475 As Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy Keynote-564 · 2023 | Their institution | $11,937 |
| PFIZER INC. · A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib With Enzalutamide in Metastatic Castrationresistant Prostate Cancer · 2021 | Their institution | $11,584 |
| Bayer HealthCare Pharmaceuticals Inc. · Bay 1841788 Mhspc · 2021 | Their institution | $11,396 |
| Genentech, Inc. · Atezolizumab in Muscle Invasive Bladder Cancer Mibc · 2024 | Their institution | $11,125 |
| Janssen Research & Development, LLC · A Phase 2, Two-Arm Multicenter, Open-Label Study To Determine the Efficacy and the Safety of Two Different Dose Regimens of A Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 in Subjects With Metastatic Or Surgically Unresectable Urothelial Cancer With Fgfr Genomic Alterations · 2020 | Their institution | $10,995 |
| Genentech, Inc. · Phase III Ipatasertib Plus Abiraterone in Mcrpc 1st Line · 2025 | Their institution | $10,560 |
| E.R. Squibb & Sons, L.L.C. · Ph-2 Dose Range With Population Pk in Rcc · 2022 | Their institution | $10,522 |
| Astellas Pharma Global Development · A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of Asg-22ce Given As Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 · 2021 | Their institution | $9,870 |
| Bayer Healthcare Pharmaceuticals Inc. · Bay 1841788, A Roll-Over Study To Provide Continued Treatment With Darolutamide in Subjects Who Were Entered in Darolutamide Studies · 2025 | Their institution | $9,820 |
| AstraZeneca Pharmaceuticals LP · Neoadjuvant Durvalumab and Chemotherapy in Variant Histology Muscle Invasive Bladder Cancer · 2021 | Their institution | $8,960 |
| E.R. Squibb & Sons, L.L.C. · Ph-2 Dose Range With Population Pk in Rcc · 2020 | Their institution | $7,834 |
| Eisai Inc. · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus Or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (Clear) · 2021 | Their institution | $7,292 |
| Exelixis Inc. · Study of Cabozantinib in Combination With Atezolizumab To Subjects With Locally Advanced Or Metastatic Solid Tumors · 2021 | Their institution | $7,177 |
| PFIZER INC. · Enfortumab Vedotin Clinical Publication Program · 2025 | This clinician | $7,140 |
| Eisai Inc. · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus Or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (Clear) · 2024 | Their institution | $7,087 |
| PFIZER INC. · A Doseescalation and Doseexpansion Study of Enfortumab Vedotin Asg22ce in Combination With Pembrolizumab Andor Chemotherapy for Treatment of Patients With Locally Advanced Or Metastatic Urothelial Cancer · 2024 | Their institution | $6,788 |
| Exelixis Inc. · A Phase 1b Dose Escalation Study of Cabozantinib (Xl184) Administered Alone Or in Combination With Atezolizumab To Subjects With Locally Advanced Or Metastatic Solid Tumors · 2025 | Their institution | $5,847 |
| Novartis Pharmaceuticals Corporation · Publication Support Provided in Connection With Heor Research · 2022 | This clinician | $5,820 |
| Merck Sharp & Dohme LLC · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab Mk-3475 As Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy Keynote-564 · 2025 | Their institution | $5,795 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Open-Label, Multi-Center, Global Study To Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed By Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer · 2023 | Their institution | $5,695 |
| PFIZER INC. · Prevail A Multinational Phase 3 Randomized Doubleblind Placebocontrolled Efficacy and Safety Study of Oral Mdv3100 in Chemotherapynaive Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy · 2020 | Their institution | $5,376 |
| Clovis Oncology, Inc. · Rucaparib in Patients With Locally Advanced Or Metastatic Urothelial Carcinoma (Atlas) · 2020 | Their institution | $5,120 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Open-Label, Multi-Center, Global Study To Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed By Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer · 2025 | Their institution | $4,897 |
| Genentech, Inc. · Bladder Cancer · 2024 | Their institution | $4,480 |
| E.R. Squibb & Sons, L.L.C. · Phase III Rcc 1l Combo - A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced Or Metastatic Renal Cell Carcinoma · 2022 | Their institution | $3,565 |
| Bayer Healthcare Pharmaceuticals Inc. · Darolutamide Roll Over Study · 2023 | Their institution | $3,465 |
| E.R. Squibb & Sons, L.L.C. · Phase III Rcc Monotherapy Vs. Everolimus Ono 4538-03 · 2021 | Their institution | $3,232 |
| Bayer Healthcare Pharmaceuticals Inc. · An Open-Label, Single Arm, Roll-Over Study To Provide Continued Treatment With Darolutamide in Participants Who Were Enrolled in Previous Bayer-Sponsored Studies · 2025 | Their institution | $2,780 |
| AstraZeneca Pharmaceuticals LP · Study of Medi4736 Durvalumab With Or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer · 2022 | Their institution | $2,629 |
| Bayer Healthcare Pharmaceuticals Inc. · Bay 1841788, A Randomized, Doubleblind, Placebocontrolled Phase III Study of Darolutamide (Odm201) Versus Placebo in Addition To Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormonesensitive Prostate Cancer · 2024 | Their institution | $2,560 |
| Astellas Pharma Global Development · A Phase 2 Open-Label Extension Study for Subjects With Prostate Cancer Who Previously Participated in An Enzalutamide Clinical Study · 2019 | Their institution | $2,515 |
| Astellas Pharma Global Development · A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of Asg-22ce Given As Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 · 2023 | Their institution | $2,355 |
| Astellas Pharma Global Development · A Phase 2 Open-Label Extension Study for Subjects With Prostate Cancer Who Previously Participated in An Enzalutamide Clinical Study · 2022 | Their institution | $2,256 |
| E.R. Squibb & Sons, L.L.C. · Phase III Rcc Monotherapy Vs. Everolimus Ono 4538-03 - A Randomized, Open-Label, Phase 3 Study of Bms-936558 Vs. Everolimus in Subjects With Advanced Or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy · 2022 | Their institution | $2,240 |
| E.R. Squibb & Sons, L.L.C. · Phase III Rcc 1l Combo - A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced Or Metastatic Renal Cell Carcinoma · 2023 | Their institution | $1,410 |
| Merck Sharp & Dohme Corporation · A Multi-Center, Double-Blind, Randomized Phase 3 Study To Compare the Efficacy and Safety of Belzutifan Mk-6482 Plus Pembrolizumab Mk- 3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma Ccrcc Post Nephrectomy 6482-022 · 2021 | Their institution | $1,116 |
| PFIZER INC. · Padcev Clinical Publication Program · 2024 | This clinician | $940 |
| E.R. Squibb & Sons, L.L.C. · Phase III Rcc Monotherapy Vs. Everolimus (Ono 4538-03) - A Randomized, Open-Label, Phase 3 Study of Bms-936558 Vs. Everolimus in Subjects With Advanced Or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy · 2023 | Their institution | $896 |
| Astellas Pharma Global Development · A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of Asg-22ce Given As Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 · 2020 | This clinician | $853 |
| Merck Sharp & Dohme LLC · Open Label Ph III Study of Belzu Zanza 1l Post Io in Arcc · 2024 | Their institution | $616 |
| Genentech, Inc. · Bladder Cancer · 2025 | Their institution | $599 |
| Merck Sharp & Dohme LLC · A Phase 3, Randomized, Double-Blind, Study of Belzutifan Zanzalintinib Versus Belzutifan Placebo in Participants With Advanced Rcc Who Have Progressed on Or After Both Pd-1,L1 and Vegf-Tki Therapies in Sequence Or in Combination Litespark-034 · 2024 | Their institution | $561 |
| Regeneron Pharmaceuticals, Inc. · Phase 1/2 Study of Regn4336 (A Psmaxcd3 Bispecific Antibody) Administered Alone Or in Combination With Cemiplimab in Patients With Metastatic Castration-Resistant Prostate Cancer · 2025 | This clinician | $485 |
| E.R. Squibb & Sons, L.L.C. · Phase III Rcc 1l Combo · 2021 | Their institution | $470 |
| Eisai Inc. · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus Or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (Clear) · 2022 | Their institution | $448 |
| Merck Sharp & Dohme Corporation · Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma Ambassador · 2019 | Their institution | $342 |
| JAZZ PHARMACEUTICALS INC. · Emerge-201: A Phase 2, Multicenter, Open-Label Study of Lurbinectedin Efficacy and Safety in Participants With Advanced Or Metastatic Solid Tumors · 2025 | Their institution | $272 |
| Regeneron Pharmaceuticals, Inc. · Phase 1/2 Study of Regn4336 (A Psmaxcd3 Bispecific Antibody) Administered Alone Or in Combination With Cemiplimab in Patients With Metastatic Castration-Resistant Prostate Cancer · 2024 | This clinician | $234 |
| JAZZ PHARMACEUTICALS INC. · Emerge-201: A Phase 2 Multicenter Open-Label Study of Lurbinectedin Efficacy and Safety in Participants With Advanced Or Metastatic Solid Tumors · 2022 | Their institution | $224 |
| Astellas Pharma Global Development · Asp1941 Phase II Clinical Study A Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response Study in Patients With Type 2 Diabetes Mellitus · 2020 | This clinician | $171 |
| Corcept Therapeutics · Cort125134-551 · 2021 | This clinician | $40 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1205913589
- Licence
- CA A49392California A49392: Current · expires 2027-03-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-11-01
- NPI last updated
- 2024-04-12
- NPI record certified
- 2024-04-12
This is when the NPI record was last certified, not a medical board exam.